Preliminary results from a recent clinical trial indicate the drug touted by US leaders as a possible treatment offers no significant benefit to patients.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.
The survey, unveiled ahead of next week's CPhI Festival of Pharma, reveals perspectives, concerns and future plans of more than 500 industry executives.
The US agency continues to issue advice for life-sciences professionals engaged in work related to the virus, and keep an eye out for fraudulent products.
The bipartisan bill calls for an assessment of the country’s pharma supply chain, including potential vulnerabilities and impact of foreign manufacturing.
This month's spotlight on new hires, promotions and company acquisitions involves Elligo Health Research, PPD, Pfizer, Covance and other industry firms.
The imaging company’s newly launched division, created to produce drug ingredients, received the loan from the US International Development Finance Corp.
The agency continues to offer advice to pharma industry professionals during the global public health crisis, and offer advice on developing solutions.
The federal agency continues to aid drug developers, trial teams and the public with advice and actions related to the virus behind the global pandemic.
The agency continues to offer advice related to drug development and clinical research during the pandemic, and take action against those falling out of line.
The federal agency continues to monitor as the virus impacts the pharma and clinical trials industries, offering advice and taking action where necessary.
A representative of the life-sciences consulting firm outlines how the federal agency has reacted to the COVID-19 pandemic, and how it might advise the industry going forward.
The federal agency continues to offer advice for healthcare and pharma industry professionals, and to take action against companies acting out of bounds.
The purchase of the Irish pharmacovigilance specialist is intended to expand’s Diamond’s European presence, and increase its senior-level industry expertise.
